Loading…

Loading grant details…

Active NON-SBIR/STTR RPGS NIH (US)

Metabolic Control and Anticancer Mechanism

$3.41M USD

Funder NATIONAL CANCER INSTITUTE
Recipient Organization Rbhs -Cancer Institute of New Jersey
Country United States
Start Date Jul 01, 2021
End Date Jun 30, 2026
Duration 1,825 days
Number of Grantees 1
Roles Principal Investigator
Data Source NIH (US)
Grant ID 10198112
Grant Description

ABSTRACT As a central controller of cancer growth and metabolism, mTORC1 pathway is commonly mutated and activated in human cancer, leading to uncontrolled growth. Cancer cells are ?addicted? to elevated mTORC1 signaling, rendering mTORC1 a desirable cancer drug target.

The highly specific mTORC1 inhibitors rapamycin analogs (rapalogs, e.g. temsirolimus) are US FDA-approved oncology drugs.

However, their clinical response has been moderate, which is in a large part due to incomplete understanding of mTORC1 signaling mechanisms underpinning rapamycin action.

In this application, we will test the central hypothesis that nuclear mTORC1 signaling promotes aerobic glycolysis, or Warburg Effect, through a long non-coding RNA (lncRNA) NEAT1- dependent mechanism, which is important for mTORC1-driven tumorigenesis and rapamycin response.

A successful completion of this project will provide a deeper understanding of this oncogenic pathway and therapeutic response to its blockage.

All Grantees

Rbhs -Cancer Institute of New Jersey

Advertisement
Discover thousands of grant opportunities
Advertisement
Browse Grants on GrantFunds
Interested in applying for this grant?

Complete our application form to express your interest and we'll guide you through the process.

Apply for This Grant